Is HER2-positive metastatic breast cancer still an incurable disease?
Mené dans 25 pays sur 808 patientes atteintes d'un cancer du sein HER2+, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout du pertuzumab à un traitement combinant trastuzumab et docétaxel (durée médiane de suivi : 8 ans)
The discovery of the HER2 oncogene was one of the most important advances in breast cancer research. 20 years ago, the advent of trastuzumab started a revolution that has continued with the introduction of additional effective targeted agents. Dual anti-HER2 targeting with trastuzumab plus pertuzumab in addition to docetaxel is an unquestionable step forward in the field. Since the publication of the first results of the CLEOPATRA trial in 2012, the pertuzumab-based regimen has become the new standard first-line treatment for patients with HER2-positive metastatic breast cancer.
The Lancet Oncology 2020